BNTX

BNTX

USD

BioNTech SE American Depositary Share

$104.780+0.460 (0.441%)

即時價格

Healthcare
生物科技
德國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$104.320

最高

$107.000

最低

$104.215

交易量

0.13M

公司基本面

市值

25.2B

行業

生物科技

國家

Germany

交易統計

平均交易量

0.85M

交易所

NMS

貨幣

USD

52週範圍

最低 $81.2當前 $104.780最高 $129.27

相關新聞

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140

HC Wainwright & Co. analyst Robert Burns maintains BioNTech with a Buy and raises the price target from $136 to $140.

查看更多
HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140
GlobeNewswire

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging

查看更多
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
GlobeNewswire

BioNTech to Host Innovation Series R&D Day on November 11, 2025

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00

查看更多
BioNTech to Host Innovation Series R&D Day on November 11, 2025
GlobeNewswire

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the

查看更多
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
Analyst Upgrades

JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120

JP Morgan analyst Jessica Fye maintains BioNTech with a Neutral and lowers the price target from $121 to $120.

查看更多
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120
GlobeNewswire

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology